Targeted drug trial aims to block cancer growth in patients with specific genetic change
NCT ID NCT04439253
First seen Nov 01, 2025 · Last updated Apr 20, 2026 · Updated 22 times
Summary
This study is testing whether the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called a ROS1 translocation. The trial includes patients with various advanced solid tumors, lymphoma, or multiple myeloma that have not responded to previous treatments. Researchers are giving crizotinib to see if blocking the ROS1 protein helps control these cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.